Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Pharmacokinetic considerations regarding tigecycline for multidrug-resistant (MDR) Klebsiella pneumoniae or MDR Acinetobacter baumannii urosepsis.

× No keyword cloud information.

10 in total

Review 1. Pharmacokinetics and pharmacodynamics of the tetracyclines including glycylcyclines.

Authors: Kenneth N Agwuh; Alasdair MacGowan
Journal: J Antimicrob Chemother Date: 2006-07-01 Impact factor: 5.790

2. Once-daily tigecycline therapy of multidrug-resistant and non-multidrug-resistant gram-negative bacteremias.

Authors: B A Cunha
Journal: J Chemother Date: 2007-04 Impact factor: 1.714

3. Single daily high-dose tigecycline therapy of a multidrug-resistant (MDR) Klebsiella pneumoniae and Enterobacter aerogenes nosocomial urinary tract infection.

Authors: B A Cunha; B McDermott; S Nausheen
Journal: J Chemother Date: 2007-12 Impact factor: 1.714

4. Treatment with tigecycline of recurrent urosepsis caused by extended-spectrum-beta-lactamase-producing Escherichia coli.

Authors: Wolfgang A Krueger; Volkhard A J Kempf; Manou Peiffer; Udo Nagele; Klaus E Unertl; Torsten H Schroeder
Journal: J Clin Microbiol Date: 2007-12-12 Impact factor: 5.948

5. Treatment of recurrent urosepsis with tigecycline: a pharmacological perspective.

Authors: Daniel Curcio
Journal: J Clin Microbiol Date: 2008-05 Impact factor: 5.948

6. Serum, tissue and body fluid concentrations of tigecycline after a single 100 mg dose.

Authors: Keith A Rodvold; Mark H Gotfried; Michael Cwik; Joan M Korth-Bradley; Gary Dukart; Evelyn J Ellis-Grosse
Journal: J Antimicrob Chemother Date: 2006-09-29 Impact factor: 5.790

Review 7. Tigecycline pharmacokinetic/pharmacodynamic update.

Authors: Alasdair P MacGowan
Journal: J Antimicrob Chemother Date: 2008-09 Impact factor: 5.790

Review 8. Tigecycline: a novel broad-spectrum antimicrobial.

Authors: Christine M Slover; Keith A Rodvold; Larry H Danziger
Journal: Ann Pharmacother Date: 2007-05-22 Impact factor: 3.154

9. Tigecycline for the treatment of patients with severe sepsis or septic shock: a drug use evaluation in a surgical intensive care unit.

Authors: Stefanie Swoboda; Michael Ober; Christian Hainer; Christoph Lichtenstern; Christoph Seiler; Constanze Wendt; Torsten Hoppe-Tichy; Markus Büchler; Markus A Weigand
Journal: J Antimicrob Chemother Date: 2008-01-25 Impact factor: 5.790

10. In vitro activity of tigecycline: MICs, MBCs, time-kill curves and post-antibiotic effect.

Authors: S Noviello; F Ianniello; S Leone; M Fiore; S Esposito
Journal: J Chemother Date: 2008-10 Impact factor: 1.714

10 in total

18 in total

1. Ertapenem-induced reduction in valproate levels: case report and review of the literature.

Authors: Duane Bates; Michael Parkins; Keltie Duggan
Journal: Can J Hosp Pharm Date: 2010-07

2. Tigecycline treatment of urinary tract infection and prostatitis: case report and literature review.

Authors: Duane Bates; Mike Parkins; Robin Hellweg; Kimberly Gibson; Jennifer M Bugar
Journal: Can J Hosp Pharm Date: 2012-05

3. Global assessment of antimicrobial susceptibility among Gram-negative organisms collected from pediatric patients between 2004 and 2012: results from the Tigecycline Evaluation and Surveillance Trial.

Authors: Sue C Kehl; Michael J Dowzicky
Journal: J Clin Microbiol Date: 2015-02-04 Impact factor: 5.948

4. Management of infections due to KPC-producing Klebsiella pneumoniae.

Authors: Stanley C Deresinski; Patricia Schirmer
Journal: F1000 Med Rep Date: 2009-10-14

5. Tigecycline does not prolong corrected QT intervals in healthy subjects.

Authors: Joan M Korth-Bradley; Paul C McGovern; Joanne Salageanu; Kyle Matschke; Anna Plotka; Sylvester Pawlak
Journal: Antimicrob Agents Chemother Date: 2013-02-12 Impact factor: 5.191

6. Antibacterial activity of eravacycline (TP-434), a novel fluorocycline, against hospital and community pathogens.

Authors: J A Sutcliffe; W O'Brien; C Fyfe; T H Grossman
Journal: Antimicrob Agents Chemother Date: 2013-08-26 Impact factor: 5.191

Review 7. β-Lactamase production in key gram-negative pathogen isolates from the Arabian Peninsula.

Authors: Hosam M Zowawi; Hanan H Balkhy; Timothy R Walsh; David L Paterson
Journal: Clin Microbiol Rev Date: 2013-07 Impact factor: 26.132

8. Successful treatment of pan-resistant Klebsiella pneumoniae pneumonia and bacteraemia with a combination of high-dose tigecycline and colistin.

Authors: Romney M Humphries; Theodoros Kelesidis; Jennifer Dien Bard; Kevin W Ward; Debika Bhattacharya; Michael A Lewinski
Journal: J Med Microbiol Date: 2010-08-05 Impact factor: 3.196

9. KPC - 3 Klebsiella pneumoniae ST258 clone infection in postoperative abdominal surgery patients in an intensive care setting: analysis of a case series of 30 patients.

Authors: Paola Di Carlo; Gaspare Gulotta; Alessandra Casuccio; Gianni Pantuso; Maurizio Raineri; Clizia Airò Farulla; Sebastiano Bonventre; Giuliana Guadagnino; Daniela Ingrassia; Gianfranco Cocorullo; Caterina Mammina; Antonino Giarratano
Journal: BMC Anesthesiol Date: 2013-07-03 Impact factor: 2.217

10. Optimal therapy for multidrug-resistant Acinetobacter baumannii.

Authors: Burke A Cunha
Journal: Emerg Infect Dis Date: 2010-01 Impact factor: 6.883